HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease.

Abstract
Levodopa-induced dyskinesia can result in significant functional disability and reduced quality of life in patients with Parkinson's disease (PD). The goal of this study was to determine if the addition of once-daily ropinirole 24-hour prolonged-release (n = 104) in PD patients not optimally controlled with levodopa after up to 3 years of therapy with less than 600 mg/d delays the onset of dyskinesia compared with increasing doses of levodopa (n = 104). During the study, 3% of the ropinirole prolonged-release group (mean dose 10 mg/d) and 17% of the levodopa group (mean additional dose 284 mg/d) developed dyskinesia (P < 0.001). There were no significant differences in change in Unified Parkinson's Disease Rating Scale activities of daily living or motor scores, suggesting comparable efficacy between the two treatments. Adverse events were comparable in the two groups with nausea, dizziness, insomnia, back pain, arthralgia, somnolence, fatigue, and pain most commonly reported. Ropinirole prolonged-release delayed the onset of dyskinesia with comparable efficacy to increased doses of levodopa in early PD patients not optimally controlled with levodopa.
AuthorsRay L Watts, Kelly E Lyons, Rajesh Pahwa, Kapil Sethi, Matthew Stern, Robert A Hauser, Warren Olanow, Alex M Gray, Bryan Adams, Nancy L Earl, 228 Study Investigators
JournalMovement disorders : official journal of the Movement Disorder Society (Mov Disord) Vol. 25 Issue 7 Pg. 858-66 (May 15 2010) ISSN: 1531-8257 [Electronic] United States
PMID20461803 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Copyright(c) 2010 Movement Disorder Society.
Chemical References
  • Antiparkinson Agents
  • Delayed-Action Preparations
  • Indoles
  • ropinirole
  • Levodopa
Topics
  • Adult
  • Age of Onset
  • Aged
  • Antiparkinson Agents (adverse effects)
  • Delayed-Action Preparations (adverse effects)
  • Disability Evaluation
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Dyskinesia, Drug-Induced (diagnosis, epidemiology, etiology)
  • Female
  • Humans
  • Indoles (adverse effects)
  • Levodopa (adverse effects)
  • Male
  • Middle Aged
  • Parkinson Disease (drug therapy, epidemiology)
  • Quality of Life (psychology)
  • Surveys and Questionnaires

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: